Compounds > 4-methylumbelliferyl iduronide
Page last updated: 2024-12-07

4-methylumbelliferyl iduronide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-methylumbelliferyl iduronide: fluorogenic substrate for (alpha-L)-iduronidase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID128746
SCHEMBL ID308321
MeSH IDM0069736

Synonyms (22)

Synonym
4-methylumbelliferyl iduronide
66966-09-4
(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(4-methyl-2-oxochromen-7-yl)oxyoxane-2-carboxylic acid
(2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(4-methyl-2-oxochromen-7-yl)oxyoxane-2-carboxylic acid
4-methylumbelliferyl-alpha-l-iduronide
4-methyl-2-oxo-2h-1-benzopyran-7-yl alpha-l-ido-pyranosiduronic acid
einecs 266-527-5
alpha-l-idopyranosiduronic acid, 4-methyl-2-oxo-2h-1-benzopyran-7-yl
4-methylumbelliferyl alpha-l-iduronide (free acid)
SCHEMBL308321
(2~{r},3~{s},4~{s},5~{r},6~{s})-6-(4-methyl-2-oxidanylidene-chromen-7-yl)oxy-3,4,5-tris(oxidanyl)oxane-2-carboxylic acid
8u8 ,
4-methyl-2-oxo-2h-1-benzopyran-7-yl hexopyranosiduronic acid
DTXSID10985697
4-methylumbelliferyl |a-l-iduronide
4-methylumbelliferyl alpha -l-iduronide (free acid)
4mu alpha-l-iduronide (free acid), 4-methylumbelliferyl iduronide, 4-methyl-2-oxo-2h-chromen-7-yl-alpha-l-idopyranosiduronic acid
PD044298
CS-0185906
HY-W127708
4-methylumbelliferyl-??-l-iduronide (free acid)
AKOS040755221
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (50.00)18.7374
1990's1 (12.50)18.2507
2000's1 (12.50)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.33 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (11.11%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
edetic acid
Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.		2.0110ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
cupric chloride
cupric chloride: RN given refers to unlabeled parent cpd. copper(II) chloride : An inorganic chloride of copper in which the metal is in the +2 oxidation state.		2.0110copper molecular entity;
inorganic chloride		EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor
iduronate
Iduronic Acid: Component of dermatan sulfate. Differs in configuration from glucuronic acid only at the C-5 position.. iduronic acid : A member of the class of iduronic acids that is the major uronic acid component of the dermatan sulfate and heparin.. idopyranuronic acid : The pyranose form of iduronic acid.. L-idopyranuronic acid : The L-stereoisomer of idopyranuronic acid.. L-iduronic acid : Any iduronic acid having L-configuration.		2.6530idopyranuronic acid;
L-iduronic acid
hymecromone
Hymecromone: A coumarin derivative possessing properties as a spasmolytic, choleretic and light-protective agent. It is also used in ANALYTICAL CHEMISTRY TECHNIQUES for the determination of NITRIC ACID.		4.480hydroxycoumarinantineoplastic agent;
hyaluronic acid synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
alpha-L-Iduronidase Deficiency
[description not available]		04.1660
Mucopolysaccharidosis I
Systemic lysosomal storage disease caused by a deficiency of alpha-L-iduronidase (IDURONIDASE) and characterized by progressive physical deterioration with urinary excretion of DERMATAN SULFATE and HEPARAN SULFATE. There are three recognized phenotypes representing a spectrum of clinical severity from severe to mild: Hurler syndrome, Hurler-Scheie syndrome and Scheie syndrome (formerly mucopolysaccharidosis V). Symptoms may include DWARFISM; hepatosplenomegaly; thick, coarse facial features with low nasal bridge; corneal clouding; cardiac complications; and noisy breathing.		04.1660
Mucopolysaccharidosis
[description not available]		01.9510
Mucopolysaccharidoses
Group of lysosomal storage diseases each caused by an inherited deficiency of an enzyme involved in the degradation of glycosaminoglycans (mucopolysaccharides). The diseases are progressive and often display a wide spectrum of clinical severity within one enzyme deficiency.		01.9510
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		01.9510